Literature DB >> 23729230

TACE-dependent TGFα shedding drives triple-negative breast cancer cell invasion.

Orsi Giricz1, Veronica Calvo, Esther A Peterson, Christiane M Abouzeid, Paraic A Kenny.   

Abstract

The epidermal growth factor receptor (EGFR) is frequently expressed in triple-negative breast cancer (TNBC) and is a marker of poor prognosis in this patient population. Because activating mutations in this kinase are very rare events in breast cancer, we screened breast tumor gene expression profiles to examine the distribution of EGFR ligand expression. Of the six known EGFR ligands, transforming growth factor alpha (TGFα) was expressed more highly in triple-negative breast tumors than in tumors of other subtypes. TGFα is synthesized as a transmembrane precursor requiring tumor necrosis factor alpha converting enzyme (TACE)/ADAM17-dependent proteolytic release to activate its receptor. In our study, we show that an inhibitor of this proteolytic release blocks invasion, migration and colony formation by several TNBC cell lines. Each of the effects of the drug was reversed upon expression of a soluble TGFα mutant that does not require TACE activity, implicating this growth factor as a key metalloproteinase substrate for these phenotypes. Together, these data demonstrate that TACE-dependent TGFα shedding is a key process driving EGFR activation and subsequent proliferation and invasion in TNBC cell lines.
Copyright © 2013 UICC.

Entities:  

Keywords:  TACE/ADAM17; epidermal growth factor receptor; transforming growth factor alpha; triple-negative breast cancer

Mesh:

Substances:

Year:  2013        PMID: 23729230      PMCID: PMC3966141          DOI: 10.1002/ijc.28295

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  31 in total

Review 1.  EGF receptor ligands.

Authors:  Raymond C Harris; Eunkyung Chung; Robert J Coffey
Journal:  Exp Cell Res       Date:  2003-03-10       Impact factor: 3.905

2.  A new diploid nontumorigenic human breast epithelial cell line isolated and propagated in chemically defined medium.

Authors:  P Briand; O W Petersen; B Van Deurs
Journal:  In Vitro Cell Dev Biol       Date:  1987-03

3.  Gradual selection of a cellular clone presenting a mutation at codon 179 of the p53 gene during establishment of the immortalized human breast epithelial cell line HMT-3522.

Authors:  C Moyret; M W Madsen; J Cooke; P Briand; C Theillet
Journal:  Exp Cell Res       Date:  1994-12       Impact factor: 3.905

Review 4.  Untangling the ErbB signalling network.

Authors:  Y Yarden; M X Sliwkowski
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

5.  TACE is required for the activation of the EGFR by TGF-alpha in tumors.

Authors:  Maria Borrell-Pagès; Federico Rojo; Joan Albanell; Josep Baselga; Joaquín Arribas
Journal:  EMBO J       Date:  2003-03-03       Impact factor: 11.598

6.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

7.  ADAM-17: a novel therapeutic target for triple negative breast cancer.

Authors:  P M McGowan; M Mullooly; F Caiazza; S Sukor; S F Madden; A A Maguire; A Pierce; E W McDermott; J Crown; N O'Donovan; M J Duffy
Journal:  Ann Oncol       Date:  2012-09-11       Impact factor: 32.976

8.  TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice.

Authors:  N C Luetteke; T H Qiu; R L Peiffer; P Oliver; O Smithies; D C Lee
Journal:  Cell       Date:  1993-04-23       Impact factor: 41.582

9.  An essential role for ectodomain shedding in mammalian development.

Authors:  J J Peschon; J L Slack; P Reddy; K L Stocking; S W Sunnarborg; D C Lee; W E Russell; B J Castner; R S Johnson; J N Fitzner; R W Boyce; N Nelson; C J Kozlosky; M F Wolfson; C T Rauch; D P Cerretti; R J Paxton; C J March; R A Black
Journal:  Science       Date:  1998-11-13       Impact factor: 47.728

10.  Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands.

Authors:  Umut Sahin; Gisela Weskamp; Kristine Kelly; Hong-Ming Zhou; Shigeki Higashiyama; Jacques Peschon; Dieter Hartmann; Paul Saftig; Carl P Blobel
Journal:  J Cell Biol       Date:  2004-03-01       Impact factor: 10.539

View more
  20 in total

Review 1.  From wavy hair to naked proteins: the role of transforming growth factor alpha in health and disease.

Authors:  Bhuminder Singh; Robert J Coffey
Journal:  Semin Cell Dev Biol       Date:  2014-03-12       Impact factor: 7.727

2.  Altered purinergic receptor-Ca²⁺ signaling associated with hypoxia-induced epithelial-mesenchymal transition in breast cancer cells.

Authors:  Iman Azimi; Hannah Beilby; Felicity M Davis; Daneth L Marcial; Paraic A Kenny; Erik W Thompson; Sarah J Roberts-Thomson; Gregory R Monteith
Journal:  Mol Oncol       Date:  2015-09-25       Impact factor: 6.603

3.  Urinary transforming growth factor α and serum α-fetoprotein as tumor markers of hepatocellular carcinoma.

Authors:  Jen-Eing Jeng; Meng-Feng Tsai; Hey-Ru Tsai; Lea-Yea Chuang; Zu-Yau Lin; Min-Yuh Hsieh; Shinn-Chern Chen; Wan-Lung Chuang; Liang-Yen Wang; Min-Lung Yu; Chia-Yen Dai; Jung-Fa Tsai
Journal:  Tumour Biol       Date:  2013-12-30

4.  A biosensor for the activity of the "sheddase" TACE (ADAM17) reveals novel and cell type-specific mechanisms of TACE activation.

Authors:  Douglas A Chapnick; Eric Bunker; Xuedong Liu
Journal:  Sci Signal       Date:  2015-02-24       Impact factor: 8.192

5.  Amphiregulin enhances alpha6beta1 integrin expression and cell motility in human chondrosarcoma cells through Ras/Raf/MEK/ERK/AP-1 pathway.

Authors:  Jui-Chieh Chen; Yu-Ju Chen; Chih-Yang Lin; Yi-Chin Fong; Chin-Jung Hsu; Chun-Hao Tsai; Jen-Liang Su; Chih-Hsin Tang
Journal:  Oncotarget       Date:  2015-05-10

6.  Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.

Authors:  F Caiazza; P M McGowan; M Mullooly; A Murray; N Synnott; N O'Donovan; L Flanagan; C J Tape; G Murphy; J Crown; M J Duffy
Journal:  Br J Cancer       Date:  2015-05-26       Impact factor: 7.640

Review 7.  A Disintegrin and Metalloprotease 17 in the Cardiovascular and Central Nervous Systems.

Authors:  Jiaxi Xu; Snigdha Mukerjee; Cristiane R A Silva-Alves; Alynne Carvalho-Galvão; Josiane C Cruz; Camille M Balarini; Valdir A Braga; Eric Lazartigues; Maria S França-Silva
Journal:  Front Physiol       Date:  2016-10-18       Impact factor: 4.566

8.  Both Specific Endothelial and Proximal Tubular Adam17 Deletion Protect against Diabetic Nephropathy.

Authors:  Vanesa Palau; Bramasta Nugraha; David Benito; Julio Pascual; Maximilian Y Emmert; Simon P Hoerstrup; Marta Riera; Maria José Soler
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

9.  Epiregulin contributes to breast tumorigenesis through regulating matrix metalloproteinase 1 and promoting cell survival.

Authors:  Mariya Farooqui; Laura R Bohrer; Nicholas J Brady; Pavlina Chuntova; Sarah E Kemp; C Taylor Wardwell; Andrew C Nelson; Kathryn L Schwertfeger
Journal:  Mol Cancer       Date:  2015-07-29       Impact factor: 27.401

10.  G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer.

Authors:  Maija Hollmén; Sinem Karaman; Simon Schwager; Angela Lisibach; Ailsa J Christiansen; Mikael Maksimow; Zsuzsanna Varga; Sirpa Jalkanen; Michael Detmar
Journal:  Oncoimmunology       Date:  2015-11-24       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.